- « Previous
- Clinical Pharmacology
- Next »
ActHIB
Clinical Pharmacology
ActHIB
Two clinical trials supported by the National Institutes of Health (NIH) have compared the anti-PRP antibody responses to three Haemophilus b conjugate vaccines in racially mixed populations of children. These studies were done in Tennessee 16 (Table 1) and in Minnesota, Missouri and Texas 17 (Table 2) in infants immunized with ActHIB® and other Haemophilus b conjugate vaccines at 2, 4 and 6 months of age. All Haemophilus b conjugate vaccines were administered concomitantly with Poliovirus Vaccine Live Oral and DTP vaccines at separate sites.
TABLE 1 16
| ANTI-PRP ANTIBODY RESPONSES IN 2-MONTH-OLD INFANTS NIH TRIAL IN TENNESSEE | |||||||||
| GEOMETRIC MEAN TITER (GMT) (µg/ mL) | |||||||||
| VACCINE | N* | Pre-Immunization | Post Second Immunization | Post Third Immunization | Post Third Immunization %>1.0µg/mL | ||||
| PRP-T† (ActHIB® ) | 65 | 0.10 | 0.30 | 3.64 | 83% | ||||
| PRP-OMP (PedvaxHIB®) | 64 | 0.11 | 0.84 | N/A | 50%** | ||||
| HbOC† (HibTITER® ) | 61 | 0.07 | 0.13 | 3.08 | Brand Name: ActHIB
Generic Name: Haemophilus b Conjugate Vaccine
WebMD Resources
Parenting and PregnancyGet tips for baby and you. | ||||
